Efficiently scaling up monoclonal antibody (mAb) manufacturing is usually a vital problem. As workflows scale towards medical and industrial manufacturing volumes, builders must be assured {that a} course of that works at small scales may be scaled up seamlessly. Sustaining product high quality and maximizing productiveness whereas staying economically possible for long-term manufacturing is important as failures or sudden outcomes may end up in pricey delays for biologic builders and affected person delays in receiving therapy.
Nevertheless, figuring out an optimum medium and feed system that does all of this is usually a time consuming course of. With speed-to-market a vital issue for fulfillment, the potential productiveness and scalability of a course of must be thought-about from the beginning.
To help builders alongside this complicated journey, progressive medium and feed programs designed particularly to help mAb manufacturing processes can supply a streamlined resolution.
The primary two white papers on this eBook current a collaboration between Thermo Fisher Scientific and the Zurich College of Utilized Sciences (ZHAW), a number one Swiss analysis establishment with longstanding life science and pharmaceutical innovation experience. ZHAW’s Centre for Biochemical Engineering and Cell Cultivation Strategies has a powerful repute for analysis excellence in cell tradition course of growth, with greater than 20 years of bioprocessing expertise.
On this collaboration, ZHAW evaluated the efficiency of two specialised mAb manufacturing options, the Gibco Environment friendly-Professional Medium and Feed System and the Gibco Excessive-Depth Perfusion (HIP) CHO Medium, two merchandise developed to boost the effectivity and scalability of mAb manufacturing processes in fed-batch and perfusion processes respectively.
This eBook explores how progressive medium and feed programs can help the profitable scale-up of mAb processes, whereas sustaining productiveness and cost-efficiency, supporting sooner speed-to-market.
